Gene expression assay and Watson for Oncology for optimization of treatment in ER-positive, HER2-negative breast cancer

BACKGROUND: Personalized treatment for cancer patients is a hot topic of debate, particularly the decision to initiate chemotherapy in patients with Estrogen receptor (ER)-positive, HER2-negative tumors in the early stages of breast cancer (BC). Owing to significant advancements in information techn...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Yun Yeong, Oh, Se Jeong, Chun, Yong Soon, Lee, Woon Kee, Park, Heung Kyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034851/
https://www.ncbi.nlm.nih.gov/pubmed/29979736
http://dx.doi.org/10.1371/journal.pone.0200100

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034851/
https://www.ncbi.nlm.nih.gov/pubmed/29979736
http://dx.doi.org/10.1371/journal.pone.0200100

Ejemplares similares